Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) Institutional Ownership

13F Institutional Holders and Ownership History from Q4 2018 to Q4 2025

Type / Class
Equity / Common Stock, par value $.001
Symbol
CLDX on Nasdaq
Shares outstanding
65,833,370
Price per share
$27.16
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares
70,727,286
Total reported value
$1,829,751,733
% of total 13F portfolios
0%
Share change
-1,999,380
Value change
-$41,022,171
Number of holders
177
Price from insider filings
$27.16
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) based on Schedule 13D/G filings

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
WELLINGTON MANAGEMENT GROUP LLP 11% +40% $191,302,079 +$55,941,805 7,394,746 +41% Wellington Management Group LLP 31 Oct 2025
Kynam Capital Management, LP 9.8% +27% $136,045,000 +$30,051,147 6,500,000 +28% Kynam Capital Management, LP 31 Mar 2025
FMR LLC 7.3% $101,670,991 4,857,668 FMR LLC 31 Dec 2024
BlackRock, Inc. 7.3% -12% $100,867,802 -$13,842,621 4,819,293 -12% BlackRock, Inc. 31 Mar 2025
Point72 Asset Management, L.P. 6.7% $90,854,558 4,464,400 Point72 Asset Management, L.P. 02 Jul 2025
Bellevue Group AG 5.4% $93,589,097 3,617,669 Bellevue Group AG 18 Aug 2025
Commodore Capital LP 4.6% -8% $78,343,026 -$8,321,474 3,028,335 -9.6% Commodore Capital LP 30 Sep 2025
PRICE T ROWE ASSOCIATES INC /MD/ 3.6% -36% $61,640,475 -$30,382,633 2,382,701 -33% T. Rowe Price Associates, Inc. 30 Sep 2025
EVENTIDE ASSET MANAGEMENT, LLC 2% $30,459,938 1,356,186 Eventide Asset Management, LLC 30 Jun 2025

As of 30 Sep 2025, 177 institutional investors reported holding 70,727,286 shares of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX). This represents 107% of the company’s total 65,833,370 outstanding shares.

Top 25 Institutional Shareholders

The largest institutional shareholders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) together control 90% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.

Institution Ownership % Shares Held Share Change % Portfolio % Holdings Value
Kynam Capital Management, LP 9.3% 6,100,729 0% 12% $157,825,859
WELLINGTON MANAGEMENT GROUP LLP 8.8% 5,800,003 +11% 0.03% $150,046,076
BlackRock, Inc. 8.4% 5,505,988 -0.79% 0% $142,439,910
FMR LLC 7.5% 4,962,088 -8.8% 0.01% $128,369,219
VANGUARD GROUP INC 6% 3,954,590 -0.06% 0% $102,305,243
Point72 Asset Management, L.P. 5.9% 3,893,942 +39% 0.22% $100,736,290
Bellevue Group AG 5.4% 3,557,669 +7.6% 1.9% $92,036,897
Commodore Capital LP 4.6% 3,028,335 -12% 3.8% $78,343,026
STATE STREET CORP 4.3% 2,842,134 +18% 0% $73,526,007
PRICE T ROWE ASSOCIATES INC /MD/ 3.6% 2,382,518 -38% 0.01% $61,636,000
Deep Track Capital, LP 3% 2,000,000 0% 1.4% $51,740,000
EVENTIDE ASSET MANAGEMENT, LLC 2.8% 1,859,095 +37% 0.79% $48,096,095
GEODE CAPITAL MANAGEMENT, LLC 2.5% 1,647,136 -1.5% 0% $42,617,698
Polar Capital Holdings Plc 2% 1,300,436 +5.9% 0.16% $33,642,279
Pictet Asset Management Holding SA 1.8% 1,211,990 -6.8% 0.03% $31,354,181
Vestal Point Capital, LP 1.8% 1,205,000 -31% 1.4% $31,173,350
NOVO HOLDINGS A/S 1.8% 1,200,000 0% 2% $31,044,000
Eversept Partners, LP 1.8% 1,153,920 +38% 2.3% $29,851,910
GOLDMAN SACHS GROUP INC 1.6% 1,029,460 +42% 0% $26,632,130
MILLENNIUM MANAGEMENT LLC 1.5% 975,195 +104% 0.02% $25,228,295
Fisher Asset Management, LLC 1.4% 927,157 +13% 0.01% $23,985,551
AMERICAN CENTURY COMPANIES INC 1.2% 815,560 +4.6% 0.01% $21,098,594
Rock Springs Capital Management LP 1.1% 721,538 -11% 1.1% $18,666,188
BAKER BROS. ADVISORS LP 1% 665,370 0% 0.12% $17,213,122
NORTHERN TRUST CORP 0.9% 595,385 +3.4% 0% $15,402,611

Institutional Holders of Celldex Therapeutics, Inc. - Common Stock, par value $.001 (CLDX) across Reporting Periods

Period Reported Shares, Excl. Options Value, Excl. Options Value Change Price (Median) Investors
2025 Q4 59,762 $1,623,382 +$845,662 $27.16 5
2025 Q3 70,727,286 $1,829,751,733 -$41,022,171 $25.87 177
2025 Q2 72,686,329 $1,479,214,886 -$18,971,957 $20.35 178
2025 Q1 73,628,376 $1,336,550,222 -$25,518,368 $18.15 170
2024 Q4 73,686,767 $1,861,792,917 -$10,935,353 $25.27 172
2024 Q3 71,809,989 $2,440,639,326 +$62,002,971 $33.99 174
2024 Q2 69,594,154 $2,575,716,559 +$1,332,092 $37.01 181
2024 Q1 69,311,318 $2,908,781,828 +$362,625,073 $41.97 196
2023 Q4 60,989,057 $2,418,831,729 +$410,573,840 $39.66 162
2023 Q3 50,572,705 $1,391,763,899 +$5,531,719 $27.52 140
2023 Q2 50,188,683 $1,702,972,802 +$19,493,416 $33.93 148
2023 Q1 49,503,692 $1,779,547,358 +$24,122,749 $35.98 158
2022 Q4 48,677,430 $2,169,609,749 -$9,316,822 $44.57 163
2022 Q3 49,338,461 $1,386,923,833 +$32,333,656 $28.11 146
2022 Q2 48,218,738 $1,300,004,065 -$45,672,202 $26.96 146
2022 Q1 49,602,527 $1,689,417,077 +$106,143,717 $34.06 157
2021 Q4 46,338,765 $1,790,195,856 +$97,400,922 $38.64 170
2021 Q3 43,227,306 $2,333,703,184 +$430,296,249 $53.99 156
2021 Q2 35,559,554 $1,189,106,240 +$60,325,552 $33.44 127
2021 Q1 34,503,199 $709,497,850 -$40,255,166 $20.60 109
2020 Q4 36,816,222 $645,045,236 +$72,177,637 $17.52 120
2020 Q3 32,156,087 $476,873,776 +$67,764,471 $14.83 82
2020 Q2 27,786,246 $361,216,517 +$310,785,532 $13.00 63
2020 Q1 3,949,694 $6,557,892 +$7,227 $1.66 32
2019 Q4 3,904,189 $8,706,543 +$447,617 $2.23 34
2019 Q3 3,708,146 $7,895,004 +$465,004 $2.13 40
2019 Q2 3,466,005 $9,286,115 +$2,108,302 $2.68 39
2019 Q1 2,603,854 $12,809,043 +$12,313,782 $4.92 39
2018 Q4 100,357 $20,000 +$20,000 $0.20 1